Boulder, Colorado - Jun 12, 2015 - Bolder BioTechnology, Inc. announced today that it has been awarded the third year of a Small Business Innovative Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). George (Joe) Cox, Ph.D., Company President said, “We are grateful to…
Read more
Bolder BioTechnology Receives Third Year of NIH Grant to Study Use of Blood Cell Growth Factors to Treat Acute Radiation Syndrome
Boulder, Colorado - Jun 12, 2015 - Bolder BioTechnology, Inc. announced today that it has been awarded the third year of a five year U01 Cooperative Research Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant is a joint research project between Bolder BioTechnology and…
Read more
Bolder BioTechnology Receives Continued NIH Support to Study Effects of Long-Acting Growth Factors for Treating Acute Radiation Syndrome
Boulder, Colorado - May 29, 2014 - Bolder BioTechnology, Inc. announced today that it has been awarded the second year of a five year U01 Cooperative Research Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant is a joint research project between Bolder BioTechnology and…
Read more
Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Company’s Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
Boulder, Colorado - August 28, 2012 - Bolder BioTechnology, Inc. announced today publication of preclinical research demonstrating utility of interleukin-11 (IL-11) and the company's long-acting IL-11 analog to prevent kidney damage from ischemia reperfusion injury in mice. This work may lead to new therapeutic approaches to prevent acute kidney injury and ischemia reperfusion injury to multiple…
Read more